Mesenchymal Stem Cells as Vectors for Cancer Therapy

  • Phuc Van PhamEmail author
  • Ngoc Bich Vu
Part of the Stem Cells in Clinical Applications book series (SCCA)


Mesenchymal stem cells (MSCs) are common stem cells in the human body. They have various properties and functions, including migration to tumors. Based on this property, MSCs have been used as vectors to deliver anti-cancer agents to tumors. To date, MSCs have been modified to express some factors or agents, including interleukin (IL)-12, IL-14, IFN-beta, IFN-gamma, TRAIL, and suicide genes/enzymes. Currently, MSCs are being modified to deliver oncolytic viruses and drug-loaded nanoparticles. In this chapter, updated information on the applications of engineered MSCs for cancer therapy will be discussed.


Mesenchymal stem cell vector Cancer treatment Cell therapy for cancer Engineered stem cells Genetically modified stem cells 





Protein thrombospondin


Acute lymphoblastic leukemia


Basic fibroblast growth factor


Epidermal growth factor


Extracellular vesicles


Ewing sarcoma


Green fluorescent protein


Hepatic growth factor


Human neural stem cells


Herpes simplex virus-1 thymidine kinase


Human umbilical cord vein endothelial cells


Interferon beta




Migration inhibitory factor


Mesenchymal stem cells


Newcastle disease virus


Stromal derived factor


Umbilical cord


Vascular endothelial growth factor



This study was supported by grant from the Ministry of Science and Technology via project No. DM.02.DA/15 “Assessment of the status, potential and capacity of research, application and development of stem cell technology in the field of medicine, pharmacy and agriculture.”


  1. Alieva M, Bago JR, Aguilar E, Soler-Botija C, Vila OF, Molet J, Gambhir SS, Rubio N, Blanco J (2012) Glioblastoma therapy with cytotoxic mesenchymal stromal cells optimized by bioluminescence imaging of tumor and therapeutic cell response. PLoS One 7:e35148CrossRefGoogle Scholar
  2. Altanerova V, Cihova M, Babic M, Rychly B, Ondicova K, Mravec B, Altaner C (2012) Human adipose tissue-derived mesenchymal stem cells expressing yeast cytosinedeaminase::uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma. Int J Cancer 130:2455–2463CrossRefGoogle Scholar
  3. Amano S, Li S, Gu C, Gao Y, Koizumi S, Yamamoto S, Terakawa S, Namba H (2009) Use of genetically engineered bone marrow-derived mesenchymal stem cells for glioma gene therapy. Int J Oncol 35:1265–1270PubMedGoogle Scholar
  4. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95CrossRefGoogle Scholar
  5. Cafforio P, Viggiano L, Mannavola F, Pelle E, Caporusso C, Maiorano E, Felici C, Silvestris F (2017) pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo. Stem Cell Res Ther 8:206CrossRefGoogle Scholar
  6. Cai C, Hou L, Zhang J, Zhao D, Wang Z, Hu H, He J, Guan W, Ma Y (2017) The inhibitory effect of mesenchymal stem cells with rAd-NK4 on liver cancer. Appl Biochem Biotechnol 183:444–459CrossRefGoogle Scholar
  7. Castleton A, Dey A, Beaton B, Patel B, Aucher A, Davis DM, Fielding AK (2014) Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. Blood 123:1327–1335CrossRefGoogle Scholar
  8. Cavarretta IT, Altanerova V, Matuskova M, Kucerova L, Culig Z, Altaner C (2010) Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol Ther 18:223–231CrossRefGoogle Scholar
  9. Chawla-Sarkar M, Leaman DW, Borden EC (2001) Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res 7:1821–1831PubMedGoogle Scholar
  10. Chen X, Lin X, Zhao J, Shi W, Zhang H, Wang Y, Kan B, Du L, Wang B, Wei Y et al (2008) A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol Ther 16:749–756CrossRefGoogle Scholar
  11. Chen Q, Cheng P, Yin T, He H, Yang L, Wei Y, Chen X (2012) Therapeutic potential of bone marrow-derived mesenchymal stem cells producing pigment epithelium-derived factor in lung carcinoma. Int J Mol Med 30:527–534CrossRefGoogle Scholar
  12. D’souza N, Burns JS, Grisendi G, Candini O, Veronesi E, Piccinno S, Horwitz EM, Paolucci P, Conte P, Dominici M (2012) MSC and tumors: homing, differentiation, and secretion influence therapeutic potential. In: Weyand B, Dominici M, Hass R, Jacobs R, Kasper C (eds) Mesenchymal stem cells-basics and clinical application II. Springer, New York, pp 209–266CrossRefGoogle Scholar
  13. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315–317CrossRefGoogle Scholar
  14. Du J, Zhou L, Chen X, Yan S, Ke M, Lu X, Wang Z, Yu W, Xiang AP (2012) IFN-gamma-primed human bone marrow mesenchymal stem cells induce tumor cell apoptosis in vitro via tumor necrosis factor-related apoptosis-inducing ligand. Int J Biochem Cell Biol 44:1305–1314CrossRefGoogle Scholar
  15. Duan X, Guan H, Cao Y, Kleinerman ES (2009) Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. Cancer 115:13–22CrossRefGoogle Scholar
  16. Dwyer RM, Ryan J, Havelin RJ, Morris JC, Miller BW, Liu Z, Flavin R, O'Flatharta C, Foley MJ, Barrett HH (2011) Mesenchymal stem cell-mediated delivery of the sodium iodide symporter supports radionuclide imaging and treatment of breast cancer. Stem Cells 29:1149–1157CrossRefGoogle Scholar
  17. Francois S, Bensidhoum M, Mouiseddine M, Mazurier C, Allenet B, Semont A, Frick J, Sache A, Bouchet S, Thierry D et al (2006) Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. Stem Cells 24:1020–1029CrossRefGoogle Scholar
  18. Friedenstein AJ, Chailakhjan RK, Lalykina KS (1970) The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 3:393–403PubMedPubMedCentralGoogle Scholar
  19. Gao P, Ding Q, Wu Z, Jiang H, Fang Z (2010) Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett 290:157–166CrossRefGoogle Scholar
  20. Garcia-Castro J, Alemany R, Cascallo M, Martinez-Quintanilla J, Arriero Mdel M, Lassaletta A, Madero L, Ramirez M (2010) Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther 17:476–483CrossRefGoogle Scholar
  21. Ghaedi M, Soleimani M, Taghvaie NM, Sheikhfatollahi M, Azadmanesh K, Lotfi AS, Wu J (2011) Mesenchymal stem cells as vehicles for targeted delivery of anti-angiogenic protein to solid tumors. J Gene Med 13:171–180CrossRefGoogle Scholar
  22. Guiho R, Biteau K, Grisendi G, Taurelle J, Chatelais M, Gantier M, Heymann D, Dominici M, Redini F (2016) TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models. Int J Cancer 139:2802–2811CrossRefGoogle Scholar
  23. Han J, Zhao J, Xu J, Wen Y (2014) Mesenchymal stem cells genetically modified by lentivirus-mediated interleukin-12 inhibit malignant ascites in mice. Exp Ther Med 8:1330–1334CrossRefGoogle Scholar
  24. Jing HX, Duan J, Zhou H, Hu QM, Lei TC (2016) Adipose-derived mesenchymal stem cell-facilitated TRAIL expression in melanoma treatment in vitro. Mol Med Rep 14:195–201CrossRefGoogle Scholar
  25. Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW (1992) Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta. J Natl Cancer Inst 84:1185–1190CrossRefGoogle Scholar
  26. Kanehira M, Xin H, Hoshino K, Maemondo M, Mizuguchi H, Hayakawa T, Matsumoto K, Nakamura T, Nukiwa T, Saijo Y (2007) Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Cancer Gene Ther 14:894–903CrossRefGoogle Scholar
  27. Kazimirsky G, Jiang W, Slavin S, Ziv-Av A, Brodie C (2016) Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL. Stem Cell Res Ther 7:149CrossRefGoogle Scholar
  28. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G (2006) Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med 203:1235–1247CrossRefGoogle Scholar
  29. Kim SM, Oh JH, Park SA, Ryu CH, Lim JY, Kim DS, Chang JW, Oh W, Jeun SS (2010) Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. Stem Cells 28:2217–2228CrossRefGoogle Scholar
  30. Kim SW, Kim SJ, Park SH, Yang HG, Kang MC, Choi YW, Kim SM, Jeun SS, Sung YC (2013) Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK. Clin Cancer Res 19:415–427CrossRefGoogle Scholar
  31. Kim N, Nam YS, Im KI, Lim JY, Lee ES, Jeon YW, Cho SG (2015) IL-21-expressing mesenchymal stem cells prevent lethal B-cell lymphoma through efficient delivery of IL-21, which redirects the immune system to target the tumor. Stem Cells Dev 24:2808–2821CrossRefGoogle Scholar
  32. Krasikova LS, Karshieva SS, Cheglakov IB, Belyavsky AV (2015) [Mesenchymal stem cells expressing cytosine deaminase inhibit growth of murine melanoma B16F10 in vivo]. Mol Biol 49:1007–1015Google Scholar
  33. Kucerova L, Matuskova M, Pastorakova A, Tyciakova S, Jakubikova J, Bohovic R, Altanerova V, Altaner C (2008) Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J Gene Med 10:1071–1082CrossRefGoogle Scholar
  34. Kucerova L, Skolekova S, Demkova L, Bohovic R, Matuskova M (2014) Long-term efficiency of mesenchymal stromal cell-mediated CD-MSC/5FC therapy in human melanoma xenograft model. Gene Ther 21:874–887CrossRefGoogle Scholar
  35. Li GC, Ye QH, Xue YH, Sun HJ, Zhou HJ, Ren N, Jia HL, Shi J, Wu JC, Dai C (2010) Human mesenchymal stem cells inhibit metastasis of a hepatocellular carcinoma model using the MHCC97-H cell line. Cancer Sci 101:2546–2553CrossRefGoogle Scholar
  36. Li X, Zhang P, Liu X, Lv P (2015) Expression of interleukin-12 by adipose-derived mesenchymal stem cells for treatment of lung adenocarcinoma. Thorac Cancer 6:80–84CrossRefGoogle Scholar
  37. Li G, Miao F, Zhu J, Chen Y (2017) Anti-angiogenesis gene therapy for hepatocellular carcinoma via systemic injection of mesenchymal stem cells engineered to secrete soluble Flt-1. Mol Med Rep 16:5799–5806CrossRefGoogle Scholar
  38. Ling X, Marini F, Konopleva M, Schober W, Shi Y, Burks J, Clise-Dwyer K, Wang R-Y, Zhang W, Yuan X et al (2010) Mesenchymal stem cells overexpressing IFN-β inhibit breast cancer growth and metastases through Stat3 signaling in a syngeneic tumor model. Cancer Microenviron 3:83–95CrossRefGoogle Scholar
  39. Liu X, Hu J, Sun S, Li F, Cao W, Wang YU, Ma Z, Yu Z (2015) Mesenchymal stem cells expressing interleukin-18 suppress breast cancer cells in vitro. Exp Ther Med 9:1192–1200CrossRefGoogle Scholar
  40. Melen GJ, Franco-Luzon L, Ruano D, Gonzalez-Murillo A, Alfranca A, Casco F, Lassaletta A, Alonso M, Madero L, Alemany R et al (2016) Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells. Cancer Lett 371:161–170CrossRefGoogle Scholar
  41. Moniri MR, Sun XY, Rayat J, Dai D, Ao Z, He Z, Verchere CB, Dai LJ, Warnock GL (2012) TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther 19:652–658CrossRefGoogle Scholar
  42. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J et al (2005) Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65:3307–3318CrossRefGoogle Scholar
  43. Niess H, Bao Q, Conrad C, Zischek C, Notohamiprodjo M, Schwab F, Schwarz B, Huss R, Jauch KW, Nelson PJ et al (2011) Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma. Ann Surg 254:767–774; discussion 774–765CrossRefGoogle Scholar
  44. Reagan MR, Seib FP, McMillin DW, Sage EK, Mitsiades CS, Janes SM, Ghobrial IM, Kaplan DL (2012) Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ. J Breast Cancer 15:273–282CrossRefGoogle Scholar
  45. Ren C, Kumar S, Chanda D, Kallman L, Chen J, Mountz JD, Ponnazhagan S (2008) Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther 15:1446–1453CrossRefGoogle Scholar
  46. Ryu CH, Park SH, Park SA, Kim SM, Lim JY, Jeong CH, Yoon WS, Oh WI, Sung YC, Jeun SS (2011) Gene therapy of intracranial glioma using interleukin 12-secreting human umbilical cord blood-derived mesenchymal stem cells. Hum Gene Ther 22:733–743CrossRefGoogle Scholar
  47. Sage EK, Kolluri KK, McNulty K, Lourenco Sda S, Kalber TL, Ordidge KL, Davies D, Gary Lee YC, Giangreco A, Janes SM (2014) Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma. Thorax 69(7):638–647. Scholar
  48. Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, Van De Water JA, Mohapatra G, Figueiredo JL, Martuza RL, Weissleder R, Shah K (2009) Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A 106:4822–4827Google Scholar
  49. Serakinci N, Christensen R, Fahrioglu U, Sorensen FB, Dagnæs-Hansen F, Hajek M, Jensen TH, Kolvraa S, Keith NW (2011) Mesenchymal stem cells as therapeutic delivery vehicles targeting tumor stroma. Cancer Biother Radiopharm 26:767–773CrossRefGoogle Scholar
  50. Shah K (2013) Stem cell therapeutics for cancer. Wiley, HobokenCrossRefGoogle Scholar
  51. Siegel RL, Miller KD, Jemal A (2017, Jan 1) Cancer statistics. CA Cancer J Clin 67(1):7–30.Google Scholar
  52. Son BR, Marquez-Curtis LA, Kucia M, Wysoczynski M, Turner AR, Ratajczak J, Ratajczak MZ, Janowska-Wieczorek A (2006) Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 24:1254–1264CrossRefGoogle Scholar
  53. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M (2002) Bone marrow-derived mesenchymal stem cells as vehicles for interferon-β delivery into tumors. Cancer Res 62:3603–3608PubMedGoogle Scholar
  54. Sun S, Liu X, Jiang D, Lu Z, Li F (2014a) [Effect of interleukin-18 gene modified human umbilical cord mesenchymal stem cells on proliferation of breast cancer cell]. Zhonghua Yi Xue Za Zhi 94:2013–2017Google Scholar
  55. Sun YP, Zhang BL, Duan JW, Wu HH, Wang BQ, Yu ZP, Yang WJ, Shan YF, Zhou MT, Zhang QY (2014b) Effect of NK4 transduction in bone marrow-derived mesenchymal stem cells on biological characteristics of pancreatic cancer cells. Int J Mol Sci 15:3729–3745CrossRefGoogle Scholar
  56. Tang Y, Li J, Zhao S, Liu J (2007) Killing effect of the herpes simplex virus thymidine kinase/ganciclovir enzyme/prodrug system on human nasopharyngeal carcinoma cells. J Int Med Res 35:433–441CrossRefGoogle Scholar
  57. van Eekelen M, Sasportas LS, Kasmieh R, Yip S, Figueiredo JL, Louis DN, Weissleder R, Shah K (2010) Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. Oncogene 29:3185–3195CrossRefGoogle Scholar
  58. Wang GX, Zhan YA, Hu HL, Wang Y, Fu B (2012) Mesenchymal stem cells modified to express interferon-beta inhibit the growth of prostate cancer in a mouse model. J Int Med Res 40:317–327CrossRefGoogle Scholar
  59. Wang Q, Zhang Z, Ding T, Chen Z, Zhang T (2013) Mesenchymal stem cells overexpressing PEDF decrease the angiogenesis of gliomas. Biosci Rep 33:e00019CrossRefGoogle Scholar
  60. Wu N, Zhang YL, Wang HT, Li DW, Dai HJ, Zhang QQ, Zhang J, Ma Y, Xia Q, Bian JM et al (2016) Overexpression of hepatocyte nuclear factor 4alpha in human mesenchymal stem cells suppresses hepatocellular carcinoma development through Wnt/beta-catenin signaling pathway downregulation. Cancer Biol Ther 17:558–565CrossRefGoogle Scholar
  61. Xie C, Xie DY, Lin BL, Zhang GL, Wang PP, Peng L, Gao ZL (2013) Interferon-beta gene-modified human bone marrow mesenchymal stem cells attenuate hepatocellular carcinoma through inhibiting AKT/FOXO3a pathway. Br J Cancer 109:1198–1205CrossRefGoogle Scholar
  62. Xu G, Jiang XD, Xu Y, Zhang J, Huang FH, Chen ZZ, Zhou DX, Shang JH, Zou YX, Cai YQ et al (2009) Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats. Cell Biol Int 33:466–474CrossRefGoogle Scholar
  63. Xu G, Guo Y, Seng Z, Cui G, Qu J (2015) Bone marrow-derived mesenchymal stem cells co-expressing interleukin-18 and interferon-beta exhibit potent antitumor effect against intracranial glioma in rats. Oncol Rep 34:1915–1922CrossRefGoogle Scholar
  64. Yan C, Song X, Yu W, Wei F, Li H, Lv M, Zhang X, Ren X (2016) Human umbilical cord mesenchymal stem cells delivering sTRAIL home to lung cancer mediated by MCP-1/CCR2 axis and exhibit antitumor effects. Tumour Biol 37:8425–8435CrossRefGoogle Scholar
  65. Yang X, Du J, Xu X, Xu C, Song W (2014) IFN-gamma-secreting-mesenchymal stem cells exert an antitumor effect in vivo via the TRAIL pathway. J Immunol Res 2014:318098PubMedPubMedCentralGoogle Scholar
  66. Zhang J, Hou L, Wu X, Zhao D, Wang Z, Hu H, Fu Y, He J (2016) Inhibitory effect of genetically engineered mesenchymal stem cells with Apoptin on hepatoma cells in vitro and in vivo. Mol Cell Biochem 416:193–203CrossRefGoogle Scholar
  67. Zhu Y, Cheng M, Yang Z, Zeng CY, Chen J, Xie Y, Luo SW, Zhang KH, Zhou SF, Lu NH (2014) Mesenchymal stem cell-based NK4 gene therapy in nude mice bearing gastric cancer xenografts. Drug Des Devel Ther 8:2449–2462CrossRefGoogle Scholar
  68. Zielske SP, Livant DL, Lawrence TS (2009) Radiation increases invasion of gene-modified mesenchymal stem cells into tumors. Int J Radiat Oncol Biol Phys 75:843–853CrossRefGoogle Scholar
  69. Zischek C, Niess H, Ischenko I, Conrad C, Huss R, Jauch K-W, Nelson PJ, Bruns C (2009) Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann Surg 250:747–753CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Laboratory of Stem Cell Research and Application & Stem Cell Institute & Cancer Research LaboratoryVNUHCM University of ScienceHo Chi Minh CityVietnam
  2. 2.Laboratory of Stem Cell Research and Application & Stem Cell InstituteVNUHCM University of ScienceHo Chi Minh CityVietnam

Personalised recommendations